Thursday, 7 March 2013

OncoMed begins phase1 clinical trial of OMP-52M51, an anticancer stem cell drug

OncoMed Pharmaceuticals just issued a press release informing us that the Phase 1 clinical trial of OMP-52M51 in patients with advanced, refractory solid tumors has begun. OMP-52M51 is a drug that attacks and destroys cancer stem cells by targeting the Notch1 receptor.

The clinical trial is carried out in numerous U.S. areas, including the South Texas Accelerated Research Therapeutics (website). The main purpose of the study is to test the drug's safety, however other drug aspects will be examined as well, including:
  • Pharmacokinetics (how the drug spreads within the body) 
  • Pharmacodynamics (the drug's effects on the body) 
  • Any evidence of improvement

According to the press release, the first patient has already been treated by Dr. Amita Patnaik of START.

“It is exciting to begin a clinical trial with this therapeutic, with a novel anticancer stem cell mechanism of action, to patients with advanced solid tumors. The companion predictive diagnostic test also makes this a cutting-edge program." said Patnaik.


You can read the official press release here.


Video about Oncomed

OncoMed Pharmaceuticals is a biomedical company, dedicated to the development of monoclonal antibodies and other agents which target and destroy cancer stem cells.


No comments:

Post a Comment

Please note that we dont offer any kind of medical advice. Questions requesting specific medical advice (e.g. where can I get this treatment, will this cure XXX condition, etc) will be published but most probably ignored by the administrators. :)

Note to spammers: You shall not pass. If you really want a link from us then consider making a stem cell related guest post !